Comparative Financials (Unaudited) (Details) - USD ($)	5 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Jul. 31, 2017	Jul. 31, 2016
Revenue:
Royalty and licensing revenue	$ 11,696,676	$ 13,262,321	$ 15,447,000	$ 18,406,142
Treatment investment revenue	65,641	250,549	105,000	39,854
Grant and contract revenue		432,000	0
Total Revenue	11,762,317	13,982,177	15,552,000	18,445,996
Operating expenses:
General and administrative	5,887,135	11,263,804	10,313,000	6,530,533
Research and development	2,486,514	8,478,817	4,857,000	3,171,599
Royalty expense	1,408,012	1,491,099	1,408,012	0
Selling expense	438,625	213,897	851,000	1,651,099
Total operating expenses	10,220,286	35,172,617	17,429,000	11,353,231
Income (loss) from operations	1,542,031	(21,190,440)	(1,877,000)	7,092,765
Total other income	6,511	46,407	68,000	38,322
Income (loss) before provision for income taxes	1,548,542	(21,144,033)	(1,809,000)	7,131,087
Provision for income taxes	169,163	51,283	797,000	550,474	$ 550,474
Net income (loss)	$ 1,379,379	$ (21,195,316)	$ (2,606,000)	$ 6,580,613